

## **Appendix D: Qualitative Interview Guides**

### **Baseline interview guide (45 minutes) – Interview #1 (before Opioid Self-Assessment Package)**

Experiences with chronic pain management	
1.	<p>a) Please tell me about your experience with choosing <u>pharmacologic</u> interventions for management of chronic pain.</p> <p>b) Please tell me about your experience with choosing <u>non-pharmacologic</u> interventions for management of chronic pain.</p>
Experiences with opioid prescribing practices	
2.	<p>How would you describe your experience with opioid prescribing to date?</p> <p><b>Probes</b></p> <ul style="list-style-type: none"> <li>• Overall, has your experience been positive or negative?</li> <li>• In your setting, how often would you prescribe opioids, if at all?</li> <li>• How confident do you feel in your opioid prescribing practices?</li> <li>• What specific areas, if any, are you interested in learning more about? Improving upon?</li> </ul>
Use of the opioid guideline	
3.	<p>a) What is your level of familiarity with the current Canadian Guideline for Safe and Effective Use of Opioids for Chronic Non-Cancer Pain (herein referred to as the “opioid guideline”)?</p> <p><i>Instruction for interviewer: If participant answers “NOT familiar with the opioid guideline”, ask question 2(b) and then proceed to question 4.</i></p> <p><b>Probes</b></p> <ul style="list-style-type: none"> <li>• In your opinion, how user-friendly is the opioid guideline?</li> <li>• How confident do you feel in your ability to use the opioid guideline in your practice?</li> </ul> <p>b) Thinking of other guidelines that you actively use/have used in your practice, what has contributed to your familiarity of these guidelines?</p> <p><b>Probes</b></p> <ul style="list-style-type: none"> <li>i) What factors help you to adhere to these guidelines? (facilitators) <ul style="list-style-type: none"> <li>• Actual facilitators (i.e., factors that are currently in place)?</li> <li>• Desired facilitators (i.e., potential or ideal factors)?</li> </ul> </li> <li>ii) What factors make it challenging for you to adhere to these guidelines? (barriers) <ul style="list-style-type: none"> <li>• Actual barriers (i.e., factors that are currently in place)?</li> <li>• Anticipated barriers (i.e., potential or perceived factors)?</li> </ul> </li> </ul>

Version 2 Date: 30 Nov-15

4.	<p>a) What factors help you to adhere to the opioid guideline? (facilitators)</p> <p><b>Probes</b></p> <ul style="list-style-type: none"> <li>• Actual facilitators (i.e., factors that are currently in place)?</li> <li>• Desired facilitators (i.e., potential or ideal factors)?</li> </ul> <p>b) What factors make it challenging for you to adhere to the guideline? (barriers)</p> <p><b>Probes</b></p> <ul style="list-style-type: none"> <li>• Actual barriers (i.e., factors that are currently in place)?</li> <li>• Anticipated barriers (i.e., potential or perceived factors)?</li> </ul>
Perceptions on implementation strategies	
5.	<p>a) Continuing medical education (or CME) has been proposed as one way to influence opioid prescribing practices. What do you think about that?</p> <p><b>Probes</b></p> <ul style="list-style-type: none"> <li>• What might this look like in your setting?</li> </ul> <p>b) Do you have experience with CME for opioid prescribing practices?</p> <ul style="list-style-type: none"> <li>• <i>If yes:</i> In your opinion, has CME been effective to address your needs? How was it effective?</li> <li>• <i>If no:</i> Do you think CME would be effective to address your needs? If no, what would be effective?</li> </ul>
6.	<p>a) What factors [might help/have helped] you to participate in CME on opioid prescribing? (facilitators)</p> <p><b>Probes</b></p> <ul style="list-style-type: none"> <li>• Actual facilitators (i.e., factors that are currently in place)?</li> <li>• Desired facilitators (i.e., potential or ideal factors)?</li> </ul> <p>b) What factors [might make/have made] it challenging for you to participate in continuing medical education on opioid prescribing? (barriers)</p> <p><b>Probes</b></p> <ul style="list-style-type: none"> <li>• Actual barriers (i.e., factors that are currently in place)?</li> <li>• Anticipated barriers (i.e., potential or perceived factors)?</li> </ul>

7.	<p>Implementation tools, such as self-assessments, checklists, chart audit tools, etc. have been proposed as an approach to quality improvement for opioid prescribing practices. What do you think about this?</p> <p><b>Probes</b></p> <ul style="list-style-type: none"> <li>• Do you think guideline implementation tools would be effective in your setting to address your needs? <ul style="list-style-type: none"> <li>○ Why or why not?</li> </ul> </li> </ul>
8.	<p>a) What other strategies might help you to implement quality improvement initiatives in the area of opioid prescribing? (facilitators)</p> <p><b>Probes</b></p> <ul style="list-style-type: none"> <li>• Actual facilitators (i.e., factors that are currently in place)?</li> <li>• Desired facilitators (i.e., potential or ideal factors that are not currently experienced)?</li> </ul> <p>b) What factors might make it challenging for you to use quality improvement tools in the area of opioid prescribing practices? (barriers)</p> <p><b>Probes</b></p> <ul style="list-style-type: none"> <li>• Actual barriers (i.e., factors that are currently in place)?</li> <li>• Anticipated barriers (i.e., potential or perceived factors)?</li> </ul>
<b>Readiness for change</b>	
9.	<p>Do you feel motivated to learn more about the Canadian Opioid Guideline?</p> <p><b>Probes</b></p> <ul style="list-style-type: none"> <li>• If yes: What is driving this motivation?</li> <li>• If no: Why not?</li> </ul>
<b>Wrap up</b>	
10.	<p>Is there anything that we did not talk about today that you would like to add? That you think would be helpful for me to know?</p>

Thank participant for their time.

Version 2 Date: 30 Nov-15

**Follow-up interview guide (45 minutes) – Interview #2** (within 2 weeks of completing the Opioid Self-Assessment Package)

**[Preamble: “Now that you have had a chance to complete the Opioid Self-Assessment Package, we would like to learn about your experiences with using the package. Your feedback will be helpful to evaluate the tools and inform future quality improvement interventions.”]**

Perceptions and usability of tools	
Online Opioid Self-Assessment Program	
1.	How would you describe the purpose of the online Opioid Self-Assessment Program - the 3 hour education module (herein referred to as the “online SAP”)?
2.	Do you feel this tool was able to meet your needs as a physician?  <b>Probes</b> <ul style="list-style-type: none"> <li>• Why/why not?</li> <li>• What specific needs, if any?</li> <li>• How?</li> </ul>
3.	a) Is there anything about the SAP in terms of <u>content</u> that you would change (e.g., reword, add or remove)?  <b>Probes</b> <ul style="list-style-type: none"> <li>• If so, what? Why?</li> </ul>
4.	a) Is there anything about the SAP in terms of <u>format</u> that you would change (e.g., add or remove)?  <b>Probes</b> <ul style="list-style-type: none"> <li>• If so, what? Why?</li> <li>• Do you have an example?</li> </ul> b) Is there anything about the SAP in terms of <u>navigation—i.e., how you were able to find your way around the SAP—that you would change?</u>  <b>Probes</b> <ul style="list-style-type: none"> <li>• If so, what? Why?</li> <li>• Do you have an example ?</li> </ul>
5.	How does the SAP compare to other alternatives that may have been considered for opioid prescribing?  <b>Probe</b> <ul style="list-style-type: none"> <li>• In your opinion, is there another program that you would rather implement?</li> </ul>
6.	How motivated do you feel to reference resources from the online SAP in the future?

Version 2 Date: 30 Nov-15

	<p><b>Probe</b></p> <ul style="list-style-type: none"> <li>• What factors motivate you?</li> </ul>
<b>Opioid Practice Self-Assessment Tool</b>	
7.	How would you describe the purpose of the Opioid Practice Self-Assessment Tool (herein referred to as the “practice self-assessment”)?
8.	<p>Do you feel the practice self-assessment tool was able to meet any of your specific needs as a physician?</p> <p><b>Probes</b></p> <ul style="list-style-type: none"> <li>• What specific needs, if any?</li> <li>• Why/why not?</li> <li>• How?</li> </ul>
9.	<p>a) Is there anything about the practice self-assessment in terms of <u>content</u> that you would change (e.g., reword, add or remove)?</p> <p><b>Probes</b></p> <ul style="list-style-type: none"> <li>• If so, what? Why?</li> </ul>
10.	<p>a) Is there anything about the practice self-assessment in terms of <u>format</u> you would change (e.g., add or remove)?</p> <p><b>Probes</b></p> <ul style="list-style-type: none"> <li>• If so, what? Why?</li> </ul> <p>b) Is there anything about the practice-self assessment in terms of <u>navigation—i.e., how you were able to find your way around the assessment</u>—which you would change? (e.g., add or remove)?</p> <p><b>Probes</b></p> <ul style="list-style-type: none"> <li>• If so, what? Why?</li> <li>• Do you have an example?</li> </ul>
11.	Which specific items in the self-assessment tool do you feel are most important, if any?
12.	<p>How does the practice self-assessment compare to other alternatives that may have been considered for opioid prescribing?</p> <p><b>Probe</b></p> <ul style="list-style-type: none"> <li>• Is there another tool that you would rather implement?</li> </ul>
13.	<p>How motivated do you feel to continue to use the practice self-assessment periodically in your practice?</p> <p><b>Probe</b></p> <ul style="list-style-type: none"> <li>• What factors motivate you?</li> </ul>

Version 2 Date: 30 Nov-15

<b>Opioid Chart Review Checklist</b>	
14.	How would you describe the purpose of the Opioid Chart Review Checklist (herein referred to as the “checklist”)?
15.	Do you feel this checklist was able to meet any of your specific needs as a physician?  <b>Probes</b> <ul style="list-style-type: none"> <li>• Why/why not?</li> <li>• Which needs, if any?</li> <li>• How?</li> </ul>
16.	a) Is there anything about the checklist in terms of <u>content</u> that you would change (e.g., reword, add or remove)?  <b>Probes</b> <ul style="list-style-type: none"> <li>• If so, what? Why?</li> </ul>
17.	a) Is there anything about the checklist in terms of <u>format</u> that you would change (e.g., add or remove)?  <b>Probes</b> <ul style="list-style-type: none"> <li>• If so, what? Why?</li> </ul> <p>b) Is there anything about the checklist in terms of <u>navigation</u> —i.e., how you were able to find your way around the checklist—that you would change (e.g., add or remove)?</p> <b>Probes</b> <ul style="list-style-type: none"> <li>• If so, what? Why?</li> </ul>
18.	Which specific items in the checklist do you feel were most important, if any?
19.	How does the checklist compare to other alternatives that may have been considered or that you know about?  <b>Probe</b> <ul style="list-style-type: none"> <li>• Is there another tool that you would rather implement?</li> <li>•</li> </ul>
20.	How motivated do you feel to continue to use the checklist periodically in your practice?  Probe <ul style="list-style-type: none"> <li>• What factors motivate you?</li> </ul>
<b>Factors affecting implementation</b>	
21.	a) What factors might help you (facilitators) to use the self assessment package (all 3 tools) in the area of opioid prescribing practices?  <b>Probes</b> <ul style="list-style-type: none"> <li>• Actual facilitators (i.e., factors that are currently in place)?</li> </ul>

Version 2 Date: 30 Nov-15

	<ul style="list-style-type: none"> <li>• Desired facilitators (i.e., potential or ideal factors that are not currently experienced)?</li> </ul> <p>b) What factors might make it challenging for you to use the self assessment package (all 3 tools) in the area of opioid prescribing practices?</p> <p><b>Probes</b></p> <ul style="list-style-type: none"> <li>• Actual barriers (i.e., factors that are currently in place)?</li> <li>• Anticipated barriers (i.e., potential or perceived factors)?</li> </ul>
22.	<p>How will available resources affect implementation in your setting?</p> <p><b>Probes</b></p> <ul style="list-style-type: none"> <li>• Time?</li> <li>• Staff?</li> <li>• Money?</li> </ul>
23.	<p>a) In your opinion, how could we engage physicians to participate in the Opioid Self-Assessment Package?</p> <p>b) In your opinion, how could we engage physicians in the use of other quality improvement initiatives/processes for opioid prescribing?</p> <p><b>Probes</b></p> <ul style="list-style-type: none"> <li>• What would those initiatives look like?</li> <li>• What would engagement strategies look like?</li> </ul>
<b>Wrap up</b>	
24.	<p>Is there anything that we did not talk about today that you would like to add? That you think would be helpful for me to know?</p>

Thank participant for their time.

**Follow-up interview guide (45 minutes) - Interview #3** (six months after completing the Opioid Self-Assessment Package)

**[Preamble: “Now that approximately six months have passed since you completed the Opioid Self-Assessment Package, we would like to learn about your experiences since using the package. Your feedback will be helpful to evaluate the tools and inform future quality improvement interventions.”]**

Experiences with chronic pain management	
1.	<p>a) Please tell me about your experience with choosing <u>pharmacologic</u> interventions for management of chronic pain, since participating in the Opioid Self-Assessment Package.</p> <p>b) Please tell me about your experience with choosing <u>non-pharmacologic</u> interventions for management of chronic pain, since participating in the Opioid Self-Assessment Package.</p>
Experiences with opioid prescribing practices	
2.	Please tell me about your experience with opioid prescribing since participating in the Opioid Self-Assessment Package.
3.	<p>Have you changed any processes or practices regarding opioid prescribing?</p> <p><b>Probes</b></p> <ul style="list-style-type: none"> <li>• If so... <ul style="list-style-type: none"> <li>○ What changed?</li> <li>○ How did it change?</li> <li>○ Why did it change?</li> </ul> </li> <li>• If not, please describe why there was no change?</li> </ul>
Use of the opioid guideline	
4.	<p>a) Please tell me about your experience using the Canadian Opioid Guidelines since participating in the Opioid Self-Assessment Package.</p> <p>b) How confident do you feel in your ability to use the opioid guideline in your practice?</p>
5.	<p>a) What factors help you to adhere to the opioid guideline? (facilitators)</p> <p><b>Probes</b></p> <ul style="list-style-type: none"> <li>• Actual facilitators (i.e., factors that are currently in place)?</li> <li>• Desired facilitators (i.e., potential or ideal factors)?</li> </ul> <p>b) What factors make it challenging for you to adhere to the guideline? (barriers)</p> <p><b>Probes</b></p> <ul style="list-style-type: none"> <li>• Actual barriers (i.e., factors that are currently in place)?</li> <li>• Anticipated barriers (i.e., potential or perceived factors)?</li> </ul>

Version 2 Date: 30 Nov-15

Use of tools	
6.	<p>What tools have you used from the SAP package, if any?</p> <p><b>Probes</b></p> <ul style="list-style-type: none"> <li>• What aspect(s) of it?</li> <li>• In what capacity?</li> <li>• How often?</li> </ul>
7.	<p>a) What factors have helped you to use the quality improvement tools from the self-assessment package in the area of opioid prescribing practices? (facilitators)</p> <p><b>Probes</b></p> <ul style="list-style-type: none"> <li>• Actual facilitators (i.e., factors that are currently in place)?</li> <li>• Desired facilitators (i.e., potential or ideal factors that are not currently experienced)?</li> </ul> <p>b) What factors have made it challenging for you to use the quality improvement tools in the area of opioid prescribing practices? (barriers)</p> <p><b>Probes</b></p> <ul style="list-style-type: none"> <li>• Actual barriers (i.e., factors that are currently in place)?</li> <li>• Anticipated barriers (i.e., potential or perceived factors)?</li> </ul>
8.	<p>How motivated do you feel to continue to use any of the tools on a periodic basis in your practice?</p> <p><b>Probes</b></p> <ul style="list-style-type: none"> <li>• What aspects of it?</li> <li>• In what capacity?</li> <li>• How often?</li> </ul>
Sustainability and scale up	
9.	<p>How will available resources affect sustaining use of the opioid quality improvement tools in your practice/institution?</p> <p><b>Probes</b></p> <ul style="list-style-type: none"> <li>• Time?</li> <li>• Staff?</li> <li>• Money?</li> <li>• Networks?</li> <li>• Systems?</li> </ul>

10.	a) Do you have any advice for physicians who are interested in improving their opioid prescribing practices?  <b>Probes</b> <ul style="list-style-type: none"><li>• Any particular strategies that you would recommend to others?</li></ul> b) Have you discussed opioid quality improvement tools with other physicians?  <b>Probes</b> <ul style="list-style-type: none"><li>• If yes, can you tell me what these conversations have involved?</li></ul>
Wrap up	
11.	Is there anything that we did not talk about today that you would like to add? That you think would be helpful for me to know?

Thank participant for their time.